S

Sun Pharmaceutical and Taro Pharmaceuticals

Consumers and third-party payers who indirectly purchased certain generic drugs may be eligible for a portion of this $200 million class action settlement.

ClosedDistrict of Columbia onlyClaim status: Closed on November 9, 2026Payout: Closed settlementNo longer claimable

About this settlement

Allegations of antitrust violations related to the pricing of certain generic drugs.

This class action settlement resolves claims that Sun Pharmaceutical and Taro Pharmaceuticals engaged in antitrust practices leading to overpayment for certain generic drugs. Eligible individuals and entities in the U.S. (excluding Indiana and Ohio) who purchased, paid for, or were reimbursed for these drugs between May 1, 2009, and Dec. 31, 2019, may be eligible to file a claim.

Who qualifies

  • Individuals and entities in the 50 United States (except Indiana and Ohio), District of Columbia, Puerto Rico, and U.S. Virgin Islands.
  • Those who indirectly purchased, paid for, or provided reimbursement for named generic drugs.
  • Purchases made between May 1, 2009, and Dec. 31, 2019, not for resale.

Closed settlement

Claim status: Closed on November 9, 2026

See active Settlements

Related settlements

Estée Lauder logo

Estée Lauder

No proof required

Up to $5,000

Claims opening soon

Audible logo

Audible

No proof required

Compensation pending

Claims opening soon

Government of Canada logo

Government of Canada

Proof required

Up to $200,000

615 days left

Meta (Facebook) logo

Meta (Facebook)

No proof required

Up to $90

Claims opening soon

Ticketmaster logo

Ticketmaster

No proof required

Compensation pending

Claims opening soon

Apple logo

Apple

No proof required

Up to $100

Claims opening soon